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SummAry
Parotid gland tumours account for 80% of all salivary gland neoplasms, 20% of these are malignant, but in daily clinical practice most 
parotid masses are operated on before obtaining the final histological diagnosis. This clinical setting further complicates the critical point 
of parotid surgery, which is the management of the facial nerve. in the present study, data were evaluated referring to 540 patients who un-
derwent parotidectomy for a mass which was discovered to be a benign (470 cases) or a malignant (70 cases) neoplasm, between november 
1994 and December 2007, at our institution.  The most significant single parameter in this series of malignancies regarding disease specific 
survival was the clinical involvement of the facial nerve at diagnosis (p = 0.006). Also for this reason, as there is no evidence that liberal 
Viith nerve sacrifice improves prognosis, when it is not clinically involved, every attempt is made to dissect and preserve it. At present, the 
most complicated situation concerning nerve preservation may be, on the other hand, recurrence of a benign tumour, in particular pleomor-
phic adenoma, which, in our series, has a higher incidence (8.3%) of permanent facial dysfunction, than surgery with nerve preservation 
for malignancy (3.7%). 
Key worDS: Parotid tumours • Prognostic factors • Facial nerve  
riASSunTo
L’80% dei tumori delle ghiandole salivari originano a livello della parotide, il 20% dei tumori parotidei sono maligni. Nella pratica 
clinica solitamente non è tuttavia possibile stabilire con certezza la diagnosi di natura di una neoformazione parotidea prima della sua 
asportazione ed esame istologico definitivo. Tale incertezza della diagnosi rende ancora più complicato l’aspetto chiave della chirurgia 
parotidea, ovvero la gestione del nervo facciale. Abbiamo valutato retrospettivamente 540 pazienti consecutivi sottoposti a parotidectomia 
presso il nostro reparto di Clinica Otorinolaringoiatrica del Policlinico Gemelli di Roma per una massa della ghiandola, risultata benigna 
in 470 e maligna in 70 casi, tra il novembre 1994 ed il dicembre 2007. Il singolo parametro clinico più significativo ai fini della prognosi è 
risultato essere il danno funzionale del nervo facciale alla diagnosi (p = 0,006). Anche per questa ragione, e dal momento che non ci sono 
prove che il sacrificio sistematico del nervo migliori la prognosi, quando questo non è clinicamente coinvolto, ogni sforzo è effettuato al 
fine di liberarlo e preservarlo. Particolarmente insidiose da questo punto di vista si sono rivelate le recidive, soprattutto se multifocali, dei 
tumori benigni, soprattutto degli adenomi pleomorfi. Queste ultime hanno un’incidenza di paresi del facciale permanente post-chirurgica 
più elevata (8,3%) persino rispetto ai tumori maligni operati con preservazione del nervo (3,7%). In questi casi è fondamentale il consenso 
del paziente che deve essere adeguatamente informato circa la possibilità di una disfunzione post-chirurgica anche permanente del VII 
nervo cranico. 
PArole ChiAVe: Tumori della parotide • Fattori prognostici • Nervo facciale
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Introduction
Salivary  cancers  account  for  approximately  3%  of  all 
head  and  neck  malignancies  diagnosed  in  the  united 
States each year; most of these are located in the parotid 
glands 1. Approximately 80% of salivary gland tumours 
occur in the parotid gland. of these, approximately 75-
80% are benign. There is no consistent correlation be-
tween the rate of tumour growth and whether a tumour is 
benign or malignant. The majority of benign tumours of 
the parotid gland are epithelial tumours. 
most benign parotid tumours present as slow growing, 
painless masses often in the tail of the parotid gland. in 
the presence of a parotid mass, physical examination is 
the first diagnostic tool, since, in most cases it guides the 
clinician in the right direction (benign versus malignant). 
ultrasonography (uS) is a low-cost modality with high 
sensitivity in detecting masses in the superficial lobe of 
the parotid gland. its inability to show part of the deeper 
parotid lobe is overcome by computerized tomography 
(CT) and/or magnetic resonance imaging (mri) which 
can be particularly useful, as complementary studies, for 
correct surgical planning. Fine-needle aspiration biopsy 
(FNAB) is also indicated by some Authors 2-4. neverthe-
less, none of these tools provide definitive information re-F. Bussu et al.
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garding the nature and the precise histology of a parotid 
mass and, furthermore open biopsy of a parotid mass is 
not recommended due to the risk of seeding in the case of 
solid malignancy. Therefore, what usually occurs in clini-
cal practice is that most parotid masses are operated upon 
in order to obtain the final histological diagnosis. obvi-
ously, lumpectomy must be avoided whenever possible 
and an oncologically safe surgical approach, involving at 
least the superficial lobe of the parotid should always be 
performed also in cases of a clinically benign lesion.
Surgery of the parotid gland is challenging because the 
Vii cranial nerve, which emerges at the stylomastoid 
foramen, enters the gland and branches out inside the 
parotid, defining the superficial and the deep lobe, and 
must always be identified and dissected when perform-
ing parotidectomy. even in the presence of normal anat-
omy and normal surrounding parotid tissue, dissection 
of the branches of the facial nerve requires patience and 
special attention both to detail and to landmarks 5. we 
always seek and dissect the facial nerve under magni-
fication. when the course of a nerve is distorted and at-
tenuated by a tumour, preservation of facial nerve fibres 
can be very difficult. experience shows that most of the 
primary salivary tumours of the parotid are found direct-
ly adjacent to at least one branch of the facial nerve, and 
rarely, if ever, will the surgeon feel that dissection of the 
nerve has been useless; also for these reasons, we believe 
that the most conservative operation should be superfi-
cial parotidectomy, also in the case of a clearly benign 
mass. Furthermore, in the event of recurrence, the risk to 
the facial nerve increases exponentially, particularly in 
the relatively frequent event of a multi-nodular relapse 
of apleomorphic adenoma 6.
enucleation alone is, therefore, inadequate for tumours of 
the parotid gland, on account both of the increased risk of 
facial nerve lesions and the increased risk of recurrence. 
Some Authors believe that the only exception to this rule 
could  be  warthin  tumours  especially  when  presenting 
posterior to the facial nerve 7.
in the present report, data are described emerging from a 
retrospective review of personal experience in this setting, 
evaluating the pathological, prognostic and surgical pa-
rameters (including complications) of a consecutive series 
of patients who underwent parotidectomy in our institu-
tion, and were found to be affected by a benign or by a 
malignant neoplasm.
Materials and methods
The data evaluated refer to approximately 540 consecu-
tive  patients  who  underwent  parotidectomy  for  benign 
and malignant neoplasms between november 1994 and 
December 2007, at the institute of otorhinolaryngology 
of università Cattolica del Sacro Cuore, Policlinico Ago-
stino gemelli, rome, italy.
For every patient, personal data were recorded including 
habits (in particular smoking and alcohol consumption), 
family history, with particular regard to tumours (salivary 
and not), clinical presentation of the parotid neoplasm. 
Data  were  collected  regarding  surgery,  complications, 
complementary and rehabilitative treatments, as well as 
respective follow-up, by means of revision of charts, di-
rect clinical re-examination and imaging of surviving pa-
tients, as well as phone calls to relatives of patients who 
had died. Before surgery, in all patients, stage had been 
defined by clinical examination and contrast enhanced CT 
scans of the head and neck, in the presence of a suspicion 
for malignancy this work-up was completed with imag-
ing of the lungs, contrast enhanced mri of the head and 
neck, salivary US, FNAB. In cases of malignancy, also 
collected were data regarding Tnm uiCC/AJCC staging 
(Vi edition - 2002).
As far as concerns clinical presentation of parotid tumours, 
especially malignant, we evaluated the involvement of the 
facial nerve, staging it according to the the House-Brack-
mann scale, and of other cranial nerves, as well as the 
involvement of other structures outside the parotid such as 
masseter, sternocleidomastoid muscle, mastoid, skin, ear 
canal, mandible, skull base. 
The masses operated upon were classified, based upon the 
site of origin, as deep or superficial, and, when they were 
demonstrated to be malignant, namely primitive (when 
the parotid was the site of origin of the neoplasm) or met-
astatic (when parotid localization was a metastasis); based 
upon the clinical history, as primary or recurrent. 
As far as concerns surgery, the parotidectomies were clas-
sified as superficial with facial preservation or total with 
nerve sacrifice (of the main trunk or of branches) and 
when extension of the resection to other structures was 
necessary this was recorded. 
in  cases  presenting  malignancy,  follow-up  data  were 
collected from the records of the visits performed in the 
multidisciplinary outpatient unit with the involvement of 
otolaryngologists (the surgeons), radiation oncologists, 
radiologists. in the first year, we recommend a CT scan 
of the parotid and neck every 4 months, and, in the second 
year every 6 months; we also suggest a chest CT, every 
year, during follow-up since lung metastases are not in-
frequent 8-10.
A statistical analysis was performed using the JmP in 
software, release 5.1 by the SAS institute. Survival curves 
were calculated from the day of surgery using the Kaplan-
meier method. Considered as endpoints for the Kaplan-
meier  overall,  disease-specific,  disease-free,  metastasis 
(regional and distant) free survival. For comparison of 
survival  curves,  both  the  log-rank  and  wilcoxon  tests 
were used. The a level was fixed at 0.05 for all the statis-
tical tests we performed.Approach and treatment of benign and malignant parotid masses
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Results
The overall study population comprised 293 males and 
247 females. none of the patients was affected by Sjö-
gren’s syndrome or by other inflammatory disease of the 
parotid. overall 470 (87%) masses were found to be be-
nign, and 70 malignant. in the “benign” group the median 
age at diagnosis was 49 years (range 4-94 years); age fol-
lowed a bimodal gaussian distribution with a peak in the 
first half of the seventh decade and another in the second 
half of the fifth decade (Fig. 1A). In the group of malig-
nancies, the median age at diagnosis was 60 years (range 
19-94 years). Age followed a unimodal gaussian distribu-
tion with a peak in the seventh decade (Fig. 1B). In the 
case of benign disease, the clinical presentation was usu-
ally a swelling of the gland, slowly growing or apparently 
stable in dimensions. in cases of malignant disease, clini-
cal presentation was an asymptomatic parotid mass in 57 
patients (81%), 13 patients came to our observation with a 
facial deficit, associated, in 3 cases, with pain, of grade ii 
(2 cases), iii (3 cases), iV (6 cases) and V (2 cases). 
Among the benign lesions, the most frequent, by far, were 
pleomorphic adenomas (almost 50%) and warthin’s tu-
mours (almost 40%) (Fig. 2); only 44 cases (less than 
10%), all pleomorphic adenomas, were localized in the 
deep  lobe. This  proportion  significantly  changes  when 
considering malignancies, 25 of which (36%) arose in the 
deep lobe. Among benign lesions, 48 pleomorphic adeno-
mas were recurrences (mostly after enucleation), 13 of 
these had undergone their first surgical operation in our 
institution (10 of them before 1994, with enucleation).
when  considering  malignancies,  primary  masses  (in-
cluding parotid nodal and extra-nodal lymphomas) were 
about 74.2% (52 patients) of the treated parotid tumours, 
11.5% (8) were recurrences of parotid malignancies in-
completely resected at other institutions and still requir-
ing revision parotidectomy, 14.3% (10) were relapses of 
a previously resected tumour outside the parotid. in the 
latter group, 1 case was local recurrence of a submandibu-
lar SCC, the others were intra-parotid nodal metastases 
from skin SCC (7 cases) and melanomas (2 cases). Three 
nodal  metastases  were  thought  to  be  primitive  parotid 
neoplasms before resection, because the patients had not 
reported the resection, considered irrelevant, of small skin 
SCCs, several months before. in 6% (4) of cases, revision 
was performed within two weeks after a first operation 
for a “histological surprise”, we considered these masses 
as primary: in all but one of these cases, no histological 
residual disease was found. Among those tumours aris-
ing primarily from the parotid (60 cases), the most fre-
quent histological finding was adenocarcinoma (15 cases, 
21%), followed by SCC (11, 16%) and lymphoma (10, 
14%) (4 nodal, 6 extra-nodal), adenoid cystic carcinoma 
(7, 10%), mucoepidermoid carcinoma (6, 9%), epithelial-
mioepithelial carcinoma (5, 7%), malignant mixed tumour 
(4, 6%), synovial sarcoma (1 case), acinic cell carcinoma 
(1 case). in the 10 operated lymphomas, cytology had not 
led to the suspicion of the final histological diagnosis.
our clinical staging of the 60 primary parotid malignan-
cies, with the aid of diagnostic imaging, had been quite 
accurate and did not usually change after the operation: 
one case, which had been considered to be a cT4n0 be-
fore surgery, was found to be a pT4n2b, and 2 cases con-
sidered cn1, which became pn0 after the neck dissection. 
Stage distribution as stated after resection (pTnm) was 
as follows: Stage i 25% (15 patients), Stage ii 33% (20), 
Stage iii 17% (10) and Stage iV 25% (15). All Stage i, 
ii and iii were n0. Among Stage iV cases, there were 6 
pT4n2b, 1 pT4n1, 1 pT3n2b, 7 pT4n0. none of the pa-
tients was m1 at diagnosis. overall 8 out of 70 (11%) of 
the patients had the diagnosis of a second metachronous 
malignant tumour previously or following the parotid ma-
lignancy: we recorded 3 adenocarcinomas of the prostate, 
2 breast cancers, 2 kidney adenocarcinomas, 1 hodgkin 
lymphoma. These metachronous malignancies were never 
the cause of death in the present series. none of the pa-
tients presenting malignancy reported a case of salivary 
malignant neoplasm among relatives. 23/60 patients with 
primary  salivary  malignant  neoplasms  reported  one  or 
more malignancies among first-degree relatives: the sites 
of such tumours were lung (4 cases), colon or rectum (4 
cases), breast (4 cases), bladder (1 case), haematopoietic 
Fig. 1. In the “benign” group age follows a bimodal Gaussian distribution 
with a peak in the first half of the seventh decade and another in the sec-
ond half of the fifth decade (Fig. 1A). In the group of malignancies, age fol-
lows an unimodal Gaussian distribution with the peak in the seventh decade 
(Fig.  1B).
Fig. 2. Distribution of histotypes in the 470 benign parotid neoplasms.F. Bussu et al.
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and lymphatic system (3 cases), larynx (1 case), oral cavity 
(1 case), stomach (6 cases), kidney (1 case), liver (1 case), 
ovary (1 case). overall, 5 out of the 6 gastric cancers oc-
curred in relatives of patients with a primary parotid can-
cer arising from the glandular epithelium (2 mucoepider-
moid carcinomas, 2 adenocarcinomas, 1 malignant mixed 
tumour). 
As far as concerns surgery, in benign lesions, superficial 
parotidectomy was performed in 396 cases, enucleation in 
10 cases of warthin’s tumour (all before 2003), total pa-
rotidectomy with facial preservation in 64 cases (mostly 
recurrences and primaries of the deep lobe). A trans-man-
dibular approach was never needed (not even in malig-
nancies), the deep lobe tumours always being resectable 
using a standard parotidectomy approach 11, by modifying 
the neck incision when needed. 
in malignancies, a superficial parotidectomy was per-
formed in 40% of cases (28 patients), total parotidec-
tomy with Viith nerve preservation in 36% (25 patients), 
total  parotidectomy  with  Viith  nerve  sacrifice  in  24% 
(17 patients). in the latter group, only in 4 patients was the 
facial nerve functioning normally at the time of surgery, 
in one of these cases, however, it was possible to preserve 
the superior (orbitofrontal) branch, in one case we recon-
structed the nerve with a sural graft. Due to the suspected 
or clinically evident involvement, resection was extended 
to  other  structures  in  15  cases  (external  auditory  canal: 
4 cases, auricle: 1, overlying skin: 9, mastoid: 2, sterno-
cleidomastoid  muscle:  7,  digastric  muscle:  7,  masseter: 
3, submandibular gland: 1). in 3 cases, in which a wide 
area of skin had to be resected, we reconstructed the defect 
with a free flap (1 DieP and 1 AlT) or a regional pedicled 
flap (pectoralis major). in 82% (58) of cases, the resection 
margins were adequate, in 4% (3) no residual disease was 
found (see above), in 14% (9) the margins were close (6) 
or positive (3). homolateral comprehensive neck dissection 
in metastases of skin neoplasms in 7 cases was performed 
(2 melanomas and 5 SCCs), and 9 comprehensive (8 modi-
fied radical type iii, 1 modified radical type i) in cn+ pri-
maries of the parotid. none of the skin SCCs were found 
to have positive nodes in the neck, both the melanomas had 
also micro-metastases in the neck; among the parotid pri-
maries 2 were found to be pN0. Furthermore, 13 homo-lat-
eral prophylactic neck dissections (selective of levels i, ii, 
iii), were performed in locally advanced primary tumours, 
with only 1 pn+ (n2b). 
Adjuvant treatment was recommended and performed in 
all the metastatic masses: radio-chemotherapy in SCCs (7 
cases) (60 gy and three cycles of concurrent CDDP 100 
mg/m on days 1, 22, and 43), IFN alpha in melanomas 
(2 cases). Primitive neoplasms of epithelial origin under-
went adjuvant radiotherapy (50-60 gy) on the surgical 
bed and on the neck nodes when indicated by principal 
international guidelines 8, i.e., in the event of intermediate 
or high grade or adenoid cystic tumours, close or positive 
margins, neural/perineural invasion, lymph node metas-
tases, lymphatic/vascular invasion, Stage iV disease, deep 
lobe salivary malignancies. when 2 or more of the above 
adverse characteristics we found to be associated, concur-
rent CDDP 100 mg/m was added on days 1, 22, and 43. 
overall 23% (16) of patients with a parotid primary tu-
mour underwent adjuvant radiochemotherapy, 20% (14) 
radiotherapy alone. lymphomas were referred to haema-
tologists and underwent chemotherapy.
early complications of surgery are the same both in the 
case  of  benign  and  malignant  lesions:  post-operative 
bleeding, within 36 hours after the parotidectomy, always 
controlled in the operatory room without further late se-
quelae, in 26 cases, and sialocele, which is by far the most 
frequent complication of surgery in our series, occurring 
in  103  patients  (19%),  but  was  always  a  self-limiting 
problem within 2 weeks of local medications, aspiration 
and compressive dressing. As fas as concerns facial nerve, 
in the cases with anatomical nerve preservation, 50 cases 
of post-operative facial weakness occurred (always more 
evident on the marginal branch), but only 6 presented a 
permanent dysfunction (2 malignancies and 4 recurrences 
of pleomorphic adenoma). Two out of these 4 recurrences 
of pleomorphic adenoma with the permanent dysfunction, 
actually had a macroscopic lesion of the facial nerve dur-
ing an extremely difficult dissection from multi-nodular 
lesions: in these cases, the facial nerve was reconstructed 
with a sural graft.
The most frequent long-term sequela, in our series, is the 
sensory deficit, probably present in every patient after pa-
rotidectomy (due to section of the great auricular nerve). 
overall, 15% of patients, in our series, complained of a 
residual sensory deficit 4 months after surgery, this rate 
increased to about 60% in the event of post-operative radi-
otherapy. overall 9 neuromas of the stump of the transect-
ed great auricular nerves were recorded, both diagnosed 
within 2 years after the parotidectomy and excised with 
no further problems. Clinical Frey syndrome (we do not 
usually  perform  objective  tests  for  detecting  subclini-
cal Frey syndrome) is not as frequent as in other series 
(17%), irradiation prevents it as it inhibits both glandular 
secretion and nerve regeneration (none of the irradiated 
patients had Frey syndrome). 
of course, it is useless to evaluate oncological outcome in 
the case of a benign lesion. Albeit, an attempt was made to 
trace the follow-up charts of every patient operated upon 
for a benign lesion, and if no record, more recent than 6 
months before, was found among the clinical reports of 
our Department then an attempt was made to contact the 
patients by phone. in this way, the clinical follow-up of 
383 out of the 470 patients with benign lesions were re-
covered. Among these, there were no cases of malignant 
transformation of a previously benign lesion. only 3 re-
currences submitted to revision surgery were recorded, 
all pleomorphic adenomas which underwent superficial Approach and treatment of benign and malignant parotid masses
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parotidectomy, in the first operation, and the recurrence 
was located in the deep lobe. The overall recurrence rate 
among primary pleomorphic adenomas with an adequate 
follow-up is, therefore, 3/134, i.e., 2.2%.
when comparing survival between the different histologi-
cal findings by log-rank and wilcoxon tests, no statisti-
cally significant differences were found (p = 0.4 and 0.53, 
respectively), recording the worst 5-year disease specific 
survival in the cases of metastatic melanomas (both dead), 
skin SCC (74%), primitive parotid SCC (68%), consist-
ently with a previous report referring to a larger series 12.
oncological outcome was then analyzed excluding tu-
mours occurring primarily in other sites, the synovial 
sarcoma and lymphomas, in order to obtain a group of 
49 malignancies of salivary origin. in this group, over-
all survival was 85% at 2 years and 72% at 5 (Fig. 3A); 
disease specific survival was 93% at 2 years and 89% 
at 5 (Fig. 3B).In this same group, no significant differ-
ences in survival were observed between lesions aris-
ing in the deep (5-year survival: 89%) and in the super-
ficial lobe (5-year survival: 92%), between resections 
with/without Viith nerve preservation (92% and 79% 
5-year survival, respectively), among the iV stages ac-
cording to Tnm classification (even if stage iV, not 
surprisingly, was less successful than the others with a 
5-year disease-specific survival of 82%). The most sig-
nificant single parameters in the salivary histotypes, as 
for disease specific survival, were the presence of posi-
tive/close margins (p = 0.01 at log-rank) and, most 
of all, the involvement of the facial nerve at diagnosis 
(p = 0.006 at Log-Rank) (Fig. 4).
Distant metastases to the lung occurred in 5 patients with 
salivary neoplasms (distant dissemination occurred in the 
patients with melanoma). At present, 3 of these patients 
are still alive with the disease, while 2 of them died due 
to the metastases. Therefore, distant metastases, together 
with local recurrence, are the main cause of cancer-related 
death (50% each) in our series; no patient died on account 
of regional relapse.
Discussion
The causes of salivary gland cancer have not been deter-
mined. Several factors have been aetiologically suggested, 
including ionizing radiation with all salivary cancers 13 and 
a familial predisposition to parotid cancer 14. Proof of cause 
and effect remains to be established, however in these pos-
tulated  associations,  and  the  aetiology  of  most  salivary 
gland cancers cannot be determined. we observed an in-
creased incidence of malignant second primary tumours 
arising from glandular epithelia in patients with a primary 
salivary tumour. it is worthwhile pointing out that our pa-
tients did not develop second primaries in the lungs, which 
is a typical occurrence in mucosal head and neck malig-
nancies 15-18. in 5/50 (10%) of our patients with a primitive 
parotid malignancy (excluding lymphomas), a family his-
tory positive for gastric cancer was recorded, which usu-
ally accounts for 1.5% of all malignancies in the general 
population of western countries 19. This would appear to be 
a quite striking observation which requires further studies 
in order to be confirmed, and may indicate common predis-
posing factors for salivary and gastric cancer. in our series, 
salivary malignancies might not have occurred among rela-
tives of the patients, because salivary cancer is altogether 
much rarer than cancer of the stomach even in susceptible 
subjects; on the other hand, a familial predisposition for 
gastric cancer has, long since, been postulated 20 21. 
The histology of primary salivary gland tumours varies 
considerably. if, on the one hand, the benign histotypes are 
not as numerous and the histopathological issues are less 
urgent, on the other, the histological diagnosis of malig-
nant lesions is a critical point. Primary malignant salivary 
gland  histotypes  have  been  classically  subdivided  into 
Fig. 3. In the salivary histo-
types,  overall  survival  in  the 
present series was 85% at 2 
years and 72% at 5 years (A); 
disease  specific  survival  was 
93% at 2 years and 89% at 5 
years (B).
Fig. 4. The most significant clinical parameter in the present series was in-
volvement of the facial nerve at diagnosis (p = 0.006 at Log-Rank), associat-
ed with a 66% 5-year disease specific survival, versus a 91% 5-year disease 
specific survival for patients with normal nerve function at diagnosis.F. Bussu et al.
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high grade and low grade, based mainly upon the criterion 
of clinical aggressiveness. Some histotypes (such as mu-
coepidermoid carcinomas) can be either high grade or low 
grade, while for others the grade is always the same (ad-
enoid cystic carcinoma is always considered high grade). 
in  the  series  described  by  the  Sloan  Kettering  Cancer 
Center (mSKCC) 9 10 22-24, 6 relatively frequent histotypes 
accounted for more than 95% of malignant salivary tu-
mours. The remaining 5% of primary salivary malignancies 
can be considered referable to at least another 10 epithelial, 
and to several mesenchymal, rare histotypes. Considering 
the overall low incidence of salivary gland cancers, each 
of these histotypes is very rare and can be very difficult 
to diagnose for the histopathologist, whose experience in 
this specific field is often limited. The distribution of the 
various histotypes encountered in the present series shows 
marked differences in incidence when compared with the 
large mSKCC series, as well as with data reported in the 
literature. These differences may be of epidemiological ori-
gin but may also be related to the readings of the various 
histopathologists; several aspects, such as the above-men-
tioned difficulties in diagnosis and the unexpected progno-
sis of SCCs in our series, which was worse than that of ad-
enoid cystic carcinomas, have led us to hypothesize that the 
subjectivity of the histopathological examinations played a 
fundamental role. For this reason, following the foundation 
of the “Multidisciplinary Head and Neck Tumor Board”, in 
our institution, in 2005, we began to submit all our samples 
(of salivary glands, as well as of the other sites in the head 
and neck) to the same histopathologist, who is interested 
in the pathological condition under study, and moreover, 
being involved in our group, is rapidly gaining experience. 
A correct histopathological diagnosis is fundamental, and 
is often the limiting factor in clinical practice, both as far as 
concerns the best management and for the evaluation of the 
results of treatment.
The parotid is the only salivary gland with intra-parenchy-
mal lymph nodes (5 to 7) that can collect metastatic cells; 
these nodes within the substance of the gland are not easily 
palpated and become visible only when they are enlarged. 
Distinguishing them from primary parotid gland tumours 
by means of palpation or by imaging can be difficult. mass-
es with an aggressive growth can, therefore, be secondary, 
most frequently due to nodal metastases from cutaneous 
squamous  cell  carcinomas  (SCC)  and  melanomas  25,  or 
related to haematologic malignancies and, in particular, to 
lymphomas. lymphomas of the parotid, arising from dif-
fuse lymphatic tissue within the gland (extra-nodal lym-
phomas), have also been described, especially in Sjögren 
disease  26. All these non-salivary malignancies often un-
dergo surgical primary treatment as if they were primarily 
salivary, since it may be impossible to define a diagnosis 
before the histological report on the surgical sample when 
the clinical history is not clear. An adequate anamnesis is, 
therefore, fundamental in at least suspecting that a parotid 
mass is secondary. Albeit, before surgery, it is mandatory 
for the surgeon to assess the risk of malignancy, because it 
affects prognosis and, most of all the attitude towards the 
facial nerve, the sacrifice of which may be necessary in sol-
id malignant neoplasms. A suspicion of malignancy, there-
fore, changes the informed consent, avoiding the legal con-
troversies related to the so-called histological surprises. in 
our opinion, histological surprises should be extremely rare: 
malignancy can almost always be at least suspected, we ex-
perienced only 4 (about 6%) histological surprises, with no 
suspicion of malignancy before the operation, in 2 of these 
cases the surprise was intra-operative, with difficulties aris-
ing in dissecting the nerve (which was anyways preserved). 
Avoiding  surprises  is  achieved  by  adequate  anamnesis, 
physical examination, imaging and FNAB. With the excep-
tion of surgical exploration, physical examination remains 
the most important tool for the experienced diagnostician: 
a hard mass with fixation is likely to be malignant; nCCn 
guidelines for the management of head and neck cancer 
suggest some suspicion criteria such as a mass > 4 cm, or 
arising from the deep lobe 8. The origin in the deep lobe 
is probably actually a suspicion criterion for malignancy, 
the frequency of deep lobe masses, in the series presented 
herewith, is definitely higher in malignant (35%) lesions 
than in benign masses (about 10%), as confirmed also by 
another recent study 21. At the first clinical observation of a 
parotid mass, symptoms and signs such as compromise in 
nerve function (10-20% of malignant parotid tumours) and/
or facial pain (10-15%) greatly increase concern regarding 
malignancy 22 27. in our series, facial deficit was practically 
as frequent as data reported in the literature (19%), while 
facial pain is definitely more unusual (4%). imaging helps 
in defining the dimensions, the site of origin, the involve-
ment in adjacent structures which can be difficult to evalu-
ate by means of physical examination (such as the parap-
haryngeal space). The role of cytological analysis achieved 
through FNAB, in cases with suspected malignancy, is still 
debated and has already been investigated by our group 3;4. 
Some Authors objected that it never modifies the clinical 
attitude because of its low sensitivity (relatively high rate 
of false negatives). This is not completely true, and, in our 
opinion, FNAB can often be helpful:
•  when it is positive, it almost confirms the suspicion of 
malignancy (high specificity) and allows us not only to 
plan the surgical procedure and possibly a reconstruc-
tive procedure on the facial nerve, but, most of all, to 
obtain an adequately informed consent regarding man-
agement of the facial nerve;
•  when surgery is not indicated due to the characteristics 
not only of the patient (poor general conditions), but also 
of the tumour (disseminated disease), making a diagno-
sis by FNAB of the parotid lesion can be important;
•  if the FNAB report reveals or suggests lymphoma, the 
diagnostic and therapeutic path changes radically and 
parotidectomy may be avoided.Approach and treatment of benign and malignant parotid masses
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however, the present series, which includes only patients 
who underwent surgery, is not an adequate model for the 
evaluation of the effectiveness of FNAB, the most useful 
role of which is to offer the possibility to avoid surgery. 
As far as concerns malignancies, as for regional lymphatic 
metastasis, in a large series reported from the memorial 
Sloan-Kettering Cancer Center, 14% of patients presented 
with palpable nodal metastases. Furthermore, 24% of the 
patients with high-grade tumours demonstrated this find-
ing, compared to only 2% of patients with low-grade le-
sions. moreover, in the group of patients who had clinically 
negative neck but underwent elective neck dissections, 49% 
of the high-grade and 7% of the low-grade tumours were 
found to have histologically positive neck 22 28. Based upon 
our data, the problem of neck metastasis would appear to 
be less crucial: in our series, we performed a prophylactic 
neck dissection in 13 cn0 cases with only a pn+ (7.7%) 
and we had no treatment failures due to regional relapse. 
neck irradiation in high risk cases (as defined above and 
by nCCn guidelines) appears to be adequate for regional 
control in most salivary cancers and in non-dissected pa-
tients, when we irradiated the surgical bed, we performed 
prophylactic irradiation also on the neck.
Findings from various studies confirm that loco-regional 
control and survival tend to be better in Stage iii/iV and 
high-grade lesions submitted to surgery and adjuvant radio-
therapy than with surgery alone 29 30 and this is confirmed 
also by international guidelines 8. This observation seems 
appopriate in particular for malignancies of the parotid 
deep lobe, because these are frequently surrounded by lit-
tle or no glandular parenchyma; thus, even the best of sur-
gical techniques consists primarily of tumour enucleation 
with a high probability of leaving in situ histological re-
sidual tumour tissue. Therefore, we performed radiother-
apy + chemotherapy in those cases of intermediate, high 
grade or adenoid cystic tumours, with close or positive 
margins, neural/perineural invasion, lymph node metas-
tases, lymphatic/vascular invasion, Stage iV disease, deep 
lobe salivary malignancies. 
Disease-specific survival decreases for many years, espe-
cially in patients with adenoid cystic carcinoma and malig-
nant mixed tumour, because of distant metastases, which 
have been reported in approximately 20% of parotid ma-
lignancies, mainly high grade, and are predictive of poor 
prognosis  22. in particular, 40% of patients with adenoid 
cystic carcinoma and 26-32% with malignant mixed tu-
mours demonstrated this feature 9 10. in all these lesions, the 
site of distant metastases is most often the lung(s). in our 
series, lung metastases occurred in 10% of patients with 
malignancies arising from salivary tissue, and distant me-
tastases is a cause of failure as frequent as local recurrence. 
nevertheless, distant metastases may not always represent 
a terminal event and, therefore, do not necessarily preclude 
the  treatment  of  primary  disease,  especially  in  adenoid 
cystic carcinoma. in our series, 3 patients are still alive with 
their metastases in situ, one of them, with adenoid cystic 
carcinoma, is alive 2 years after the diagnosis of pulmonary 
relapse. it is worthwhile pointing out that in the present se-
ries none of the patients had a diagnosed distant metastases 
when parotidectomy was performed. 
overall, the prognosis for parotid gland cancer is better 
than that for the submandibular gland lesions: 50-81% 
5-year survival is reported for the former and 30-50% 
for the latter 22. in the present series, 5-year overall sur-
vival and 5-year disease-specific survival were, respec-
tively, 72% and 89% in patients with primary salivary 
cancers  of  the  parotid.  Several  previous  investigations 
showed that advanced stage, higher histological grade, 
and sub-mandibular location were prognostic for poorer 
outcome and, moreover, differences in histological fea-
tures were reported to affect the natural history 9 14 23 31-34. 
in our series, grading was not always assessed by histo-
pathologists and histotype was not demonstrated to sig-
nificantly affect prognosis, probably also on account of 
all the above-mentioned difficulties of histopathological 
diagnosis and the lack, in the years under examination, of 
a dedicated histopathologist in our institution. Viith nerve 
involvement and positive/close margins in the histologi-
cal sample are the only clinical parameters, at diagnosis, 
associated with significant differences in survival in our 
series. in particular, Viith nerve clinical involvement, at 
diagnosis, is the most significant prognostic marker (Fig. 
4, p = 0.006 at log-rank) in agreement with most of the 
data in the literature 35 36.
The significance of positive/close margins might suggest 
extending the indications for nerve sacrifice, because the 
attempt  to  preserve  the  nerve  sometimes  leads  the  sur-
geon to leave microscopic (or even macroscopic) disease 
behind.  nevertheless,  such  a  “destructive”  attitude  with 
liberal resection of the facial nerve (and of other impor-
tant structures) no longer dominates surgical philosophy. 
instead, the surgeon’s reliance upon post-operative radia-
tion therapy to manage histological disease and the likeli-
hood of distant metastases make many surgeons reluctant 
to sacrifice a functioning facial nerve also in the event of a 
clear malignancy which is difficult to dissect. if we analyze 
our results more in-depth, we come to share this form of 
surgical minimalism which has been gaining consent over 
the last few years. in fact, facial nerve sacrifice, in our se-
ries, is associated with a less favourable survival, even if 
not of statistical significance, because the most significant 
prognostic parameter in our series, the clinical involvement 
on Viith nerve, always required resection of this structure, 
which clearly did not help in improving prognosis.
At present, the worst problems in dissecting the nerve, 
especially in consideration of the benign histology, are 
encountered  in  multi-nodular  recurrences  of  pleomor-
phic adenomas, in the present series, as in others in the 
literature 6 37 38. in fact, the incidence of permanent facial 
dysfunction is markedly higher in in cases of recurrence F. Bussu et al.
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of pleomorphic adenomas (8.3%) than in cases of surgery 
with nerve preservation for malignancy (3.7%). in our 
opinion, in these cases, the best defense for the surgeon is 
adequate informed consent of the patients, who must be 
informed regarding the concrete possibility of facial palsy 
following an operation for a benign disease. This event is 
the main argument in favour of extensive surgery (at least 
a superficial parotidectomy) in pleomorphic adenomas. 
on the other hand, we do not believe in the usefulness 
of irradiation in these cases, as it can make subsequent 
surgery even more complicated, without significant data 
regarding the clinical effectiveness 37 39.
most of our patients operated upon for a malignancy with 
positive margins had undergone total parotidectomy with 
nerve  sacrifice,  which  is,  therefore,  not  a  solution  for 
the issues of margins. in fact, when available on the his-
topathological report, the positive margins were found to 
be usually outside the parotid, due to the involvement of 
other structures, so probably a more aggressive attitude is 
warranted on extra-glandular structures, possibly resort-
ing more often to reconstructive techniques.
in our opinion, clinical nerve dysfunction and extra-pa-
rotid extension, often not associated with bulky tumours, 
in our experience (Fig. 5), are, in themselves, expression 
of intrinsically more aggressive tumours and can be inter-
preted as independent prognostic factors. 
Conclusions
results emerging from the present study confirm many 
of the well-known prognostic parameters for parotid ma-
lignant neoplasms and data related to the clinical history, 
which is often affected by distant metastases.
Clinical involvement of the Viith nerve and positive mar-
gins after resection are the most significant of these pa-
rameters, as they are probably the expression of an intrin-
sic “biological” potential for malignancy.
on the other hand, there is no evidence showing that liberal 
Viith nerve sacrifice improves prognosis, thus our attitude 
remains to resect the nerve when it is clinically involved 
and when it is totally embedded in a clearly malignant 
neoplasm, but to, at least, attempt to dissect and preserve 
it in all other cases. This guidance is strengthened by the 
consideration that ultimate diagnosis of malignancy, and 
definition of histotype, always rely on final histological 
findings on the surgical sample (often with the help of im-
munohistochemistry) and that, at present, neither clinical 
and surgical feeling, nor frozen section, or FNAB can pro-
vide reliable and legally acceptable indications for Viith 
nerve sacrifice.
At present, the worst problems concerning the nerve may 
be encountered in the eventual resection of recurrences 
of pleomorphic adenomas 6 37 38; in these cases, adequate 
informed consent of the patients is mandatory.
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